Ocular Therapeutix, Inc. (OCUL)Healthcare | Biotechnology | Bedford, United States | NasdaqGM
9.88 USD
-0.32
(-3.137%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:56 a.m. EDT
The immediate outlook is driven by a distinct divergence between the company's precarious financial reality and aggressive speculative positioning. Fundamentally, Ocular Therapeutix remains a cash-burning biotech with negative operating margins, negative free cash flow, and no dividend history, leaving it entirely dependent on capital markets or future drug approvals. However, the options chain tells a different story for the near term: traders are ignoring the balance sheet risks to pile into deep out-of-the-money calls ($20 strike) and heavy ATM volume, while virtually no one is buying protection. This suggests the market is pricing in a binary event—likely the upcoming retina meeting data or FDA feedback on AXPAXLI—that could instantly validate the high valuation multiples currently trading at 43x sales. While the long-term fundamentals remain fragile due to the lack of profitability and reliance on external funding, the current options flow indicates a high-conviction, albeit risky, bet on a catalyst-driven price surge in the coming weeks. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.058470 |
| AutoTheta | 0.058585 |
| AutoARIMA | 0.058744 |
| AutoETS | 0.058744 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.212 |
| Excess Kurtosis | -1.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.663 |
| Revenue per Share | 0.259 |
| Market Cap | 2,163,328,256 |
| Forward P/E | -6.43 |
| Beta | 0.88 |
| Website | https://www.ocutx.com |
As of July 11, 2026, 2:56 a.m. EDT: Speculators are aggressively positioning for upside, evidenced by massive open interest and volume at $20 strikes for December and January expirations, alongside heavy call flow at the $10 ATM level. Conversely, put activity is negligible, with almost zero volume in the nearest expiration and very low open interest across the board, indicating a lack of hedging demand and a one-sided bullish sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.109107316 |
| Address1 | 14 Crosby Drive |
| Address2 | 3rd Floor |
| All Time High | 44.19 |
| All Time Low | 1.995 |
| Ask | 12.55 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 2,275,070 |
| Average Daily Volume3 Month | 2,902,621 |
| Average Volume | 2,902,621 |
| Average Volume10Days | 2,275,070 |
| Beta | 0.88 |
| Bid | 7.31 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 2.657 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.88 |
| Current Ratio | 14.806 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 10.185 |
| Day Low | 9.76 |
| Debt To Equity | 13.663 |
| Display Name | Ocular Therapeutix |
| Earnings Call Timestamp End | 1,777,982,400 |
| Earnings Call Timestamp Start | 1,777,982,400 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,933,000 |
| Earnings Timestamp Start | 1,785,933,000 |
| Ebitda | -294,815,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.346 |
| Enterprise To Revenue | 30.287 |
| Enterprise Value | 1,576,091,392 |
| Eps Current Year | -1.5525 |
| Eps Forward | -1.5375 |
| Eps Trailing Twelve Months | -1.44 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.2279 |
| Fifty Day Average Change | 0.65210056 |
| Fifty Day Average Change Percent | 0.070666194 |
| Fifty Two Week Change Percent | -10.910731 |
| Fifty Two Week High | 16.44 |
| Fifty Two Week High Change | -6.5600004 |
| Fifty Two Week High Change Percent | -0.39902678 |
| Fifty Two Week Low | 6.23 |
| Fifty Two Week Low Change | 3.65 |
| Fifty Two Week Low Change Percent | 0.5858748 |
| Fifty Two Week Range | 6.23 - 16.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,406,295,000,000 |
| Float Shares | 184,373,380 |
| Forward Eps | -1.5375 |
| Forward P E | -6.4260163 |
| Free Cashflow | -148,761,504 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 325 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -175,055,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00936 |
| Held Percent Institutions | 0.95733 |
| Implied Shares Outstanding | 218,960,358 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. |
| Long Name | Ocular Therapeutix, Inc. |
| Market | us_market |
| Market Cap | 2,163,328,256 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_41955650 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -290,497,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,166,612,742 |
| Number Of Analyst Opinions | 11 |
| Open | 10.15 |
| Operating Cashflow | -226,204,992 |
| Operating Margins | -8.65461 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 781 357 4000 |
| Pre Market Change | 0.069999695 |
| Pre Market Change Percent | 0.70849895 |
| Pre Market Price | 9.95 |
| Pre Market Time | 1,784,034,818 |
| Previous Close | 10.2 |
| Price Eps Current Year | -6.3639293 |
| Price Hint | 2 |
| Price To Book | 3.7184794 |
| Price To Sales Trailing12 Months | 41.572086 |
| Profit Margins | 0.0 |
| Quick Ratio | 14.493 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.32 |
| Regular Market Change Percent | -3.13725 |
| Regular Market Day High | 10.185 |
| Regular Market Day Low | 9.76 |
| Regular Market Day Range | 9.76 - 10.185 |
| Regular Market Open | 10.15 |
| Regular Market Previous Close | 10.2 |
| Regular Market Price | 9.88 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,400,356 |
| Return On Assets | -0.32878 |
| Return On Equity | -0.68554 |
| Revenue Growth | 0.008 |
| Revenue Per Share | 0.259 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 218,960,358 |
| Shares Percent Shares Out | 0.12189999 |
| Shares Short | 26,695,136 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 25,086,045 |
| Short Name | Ocular Therapeutix, Inc. |
| Short Percent Of Float | 0.144 |
| Short Ratio | 8.46 |
| Source Interval | 15 |
| State | MA |
| Symbol | OCUL |
| Target High Price | 34.0 |
| Target Low Price | 18.0 |
| Target Mean Price | 27.09091 |
| Target Median Price | 28.0 |
| Total Cash | 666,699,008 |
| Total Cash Per Share | 3.045 |
| Total Debt | 79,462,000 |
| Total Revenue | 52,038,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.311325 |
| Two Hundred Day Average Change | -0.43132496 |
| Two Hundred Day Average Change Percent | -0.041830216 |
| Type Disp | Equity |
| Volume | 1,400,356 |
| Website | https://www.ocutx.com |
| Zip | 1,730 |